

Company Overview

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system conditions. The company has five novel and differentiated drug development programs. OLINVYK™ is approved by the FDA. Please see **Important Safety Information** including **Boxed Warning** in the full prescribing information available at OLINVYK.com. The company has four investigational drug candidates including TRV 027 for acute respiratory distress syndrome and abnormal clotting, TRV 250 for the acute treatment of migraine and TRV 734 for maintenance treatment of opioid use disorder. The company has also identified TRV 045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain and CNS disorders.

Trevena, Inc. Appoints Marvin H. Johnson, Jr. to Board of Directors

Mar 18 2021, 7:00 AM EDT

Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results

Mar 9 2021, 7:00 AM EST

Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

Mar 5 2021, 7:00 AM EST

Stock Overview

Symbol	TRVN
Exchange	Nasdaq
Market Cap	275.78m
Last Price	\$1.71
52-Week Range	\$0.61 - \$3.69

04/14/2021 04:00 PM EDT

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
Managing Director
T: 617-430-7576
daniel@lifesciadvisors.com

Management Team

Carrie L. Bourdow

President and Chief Executive Officer

Scott Applebaum

Chief Legal and Compliance Officer, SVP of Regulatory Affairs and Corporate Secretary

Mark A. Demitrack, MD

Senior Vice President, Chief Medical Officer

Barry Shin

Senior Vice President, Chief Financial Officer

Robert T. Yoder

Senior Vice President, Chief Commercial Officer

Joel S. Solomon, Esq.

Vice President, Legal & Compliance

Linda Wase, MD

Vice President, Medical Affairs

Michael S. Kramer

Vice President, Scientific Operations & Alliance Management

Katrine Sutton

Vice President, Finance Planning & Analysis

Michael J. Fossler, Pharm. D., Ph. D., F.C.P.

Vice President, Clinical Development and Quantitative Sciences

Angela Bagley

Vice President, CMC and Supply Chain Operations

Trevena, Inc.

955 Chesterbrook Blvd
Suite 110
Chesterbrook, PA 19087

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.